Yksityiskohtainen opas tulossa pian
Työskentelemme kattavan oppaan parissa kohteelle GAD-7 Anxiety Scale. Palaa pian katsomaan vaiheittaiset selitykset, kaavat, käytännön esimerkit ja asiantuntijavinkit.
The Generalised Anxiety Disorder 7-item scale (GAD-7) is a validated, brief self-report questionnaire for screening and measuring the severity of generalised anxiety disorder (GAD) and anxiety symptoms more broadly. Developed by Robert Spitzer and colleagues and published in the Archives of Internal Medicine in 2006, the GAD-7 was derived from the DSM-IV diagnostic criteria for generalised anxiety disorder and validated in a large primary care population of over 2,700 patients. The seven items assess the frequency of the following symptoms over the past 2 weeks: feeling nervous, anxious, or on edge; inability to stop or control worrying; worrying too much about different things; trouble relaxing; being so restless that it is hard to sit still; becoming easily annoyed or irritable; and feeling afraid as if something awful might happen. Each item is scored on a 4-point scale (0 = not at all, 1 = several days, 2 = more than half the days, 3 = nearly every day), giving a total score of 0–21. Severity bands are: 0–4 (minimal anxiety), 5–9 (mild anxiety), 10–14 (moderate anxiety), and 15–21 (severe anxiety). A score of 10 or above is the recommended clinical action threshold, with sensitivity of 89% and specificity of 82% for GAD. The GAD-7 is also sensitive for panic disorder (sensitivity 74%), social anxiety disorder (72%), and post-traumatic stress disorder (66%), making it a useful broad-spectrum anxiety screening tool rather than a GAD-specific instrument. It is frequently used alongside the PHQ-9 in stepped care mental health services, together providing a comprehensive picture of both depressive and anxiety symptom burden.
GAD-7 Total = sum of 7 items (each 0–3); 0–4=minimal, 5–9=mild, 10–14=moderate, 15–21=severe anxiety; ≥10 = clinical action threshold
- 1Step 1 — Administer the questionnaire: Ask the patient to rate each of the 7 items for the past 2 weeks using the response options: 0=Not at all, 1=Several days, 2=More than half the days, 3=Nearly every day.
- 2Step 2 — Item 1: 'Feeling nervous, anxious, or on edge.'
- 3Step 3 — Item 2: 'Not being able to stop or control worrying.'
- 4Step 4 — Item 3: 'Worrying too much about different things.'
- 5Step 5 — Items 4–7: 'Trouble relaxing; so restless it is hard to sit still; becoming easily annoyed or irritable; feeling afraid as if something awful might happen.'
- 6Step 6 — Calculate total: Sum all 7 items (0–21). Assign severity band.
- 7Step 7 — Act on score: 0–4: reassure; 5–9: self-help resources, watchful waiting; 10–14: structured psychological therapy (CBT); 15–21: high-intensity CBT, consider pharmacotherapy (SSRI/SNRI/pregabalin), specialist referral.
Self-help resources; sleep hygiene; relaxation techniques; watchful waiting; reassess at 4 weeks
Total 6 = mild anxiety band (5–9). Below clinical action threshold. Education about anxiety, self-help CBT resources, and monitoring. Review if symptoms persist >4 weeks.
IAPT referral for structured CBT; SSRI (sertraline 50 mg OD) as pharmacotherapy option
Total 12 = moderate anxiety (10–14). Meets action threshold. NICE recommends high-intensity CBT or pharmacotherapy (SSRI first line, e.g., sertraline). Medication + therapy is most effective.
Urgent IAPT referral or specialist CMHT input; SSRI + structured CBT; consider short-term benzodiazepine only if acute distress prevents engagement with therapy
Score ≥15 = severe anxiety. Significant functional impairment likely. Specialist psychological therapy and pharmacotherapy combination is indicated. Benzodiazepines are not recommended long-term due to dependence risk.
Continue treatment; target remission (GAD-7 <5); maintain SSRI for 6–12 months minimum after remission
≥5-point reduction = clinically significant response. Moving from severe to mild is a major improvement. Maintain treatment and monitor; do not stop antidepressants within 2–3 months of response.
Primary care physicians and internists use Gad7 during routine clinical assessments to screen patients, establish baselines for longitudinal monitoring, and identify individuals who may need referral to specialists for further diagnostic evaluation or therapeutic intervention.
Hospital clinical pharmacists apply Gad7 to verify drug dosing calculations, particularly for medications with narrow therapeutic indices like warfarin, aminoglycosides, and chemotherapy agents where patient-specific factors such as renal function and body weight critically affect safe dosing ranges.
Public health epidemiologists use Gad7 in population-level screening programs to calculate disease prevalence, assess screening test sensitivity and specificity, and determine the number needed to screen to detect one case in various demographic subgroups.
Clinical researchers incorporate Gad7 into study design protocols to calculate sample sizes, determine statistical power for detecting clinically meaningful differences, and establish inclusion criteria based on quantitative physiological thresholds.
Pediatric versus adult reference ranges
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in gad7 calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
Pregnancy and hormonal variations
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in gad7 calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
Extreme body composition
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in gad7 calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
Social Anxiety vs GAD
GAD involves pervasive, uncontrollable worry across multiple life domains. Social anxiety disorder is specifically triggered by social situations, with intense fear of scrutiny or embarrassment. GAD-7 detects both but does not differentiate. A detailed clinical interview determining whether anxiety is pervasive or situation-specific is essential, as psychological and pharmacological treatments differ between GAD and social anxiety.
| Score | Severity | Recommended Action |
|---|---|---|
| 0–4 | Minimal | Reassure; psychoeducation; monitor if symptoms persist |
| 5–9 | Mild | Self-help resources; watchful waiting; relaxation techniques |
| 10–14 | Moderate | Structured CBT (high-intensity); consider SSRI (sertraline) |
| 15–21 | Severe | High-intensity CBT + SSRI/SNRI; consider specialist referral (CMHT) |
What is the difference between GAD-7 and GAD-2?
The GAD-2 uses only the first 2 items of the GAD-7 (feeling nervous/anxious and inability to control worrying). A GAD-2 score ≥3 has 86% sensitivity for GAD and is used as an ultra-brief triage tool. Patients who screen positive with GAD-2 should complete the full GAD-7. GAD-2 is useful in high-volume settings like acute medical admissions where time is limited.
Is GAD-7 specific to generalised anxiety disorder?
No — GAD-7 also screens for panic disorder, social anxiety disorder (social phobia), and post-traumatic stress disorder with sensitivities of 74%, 72%, and 66% respectively at a threshold of ≥10. It is better described as a broad-spectrum anxiety severity measure. For more specific disorder assessment, condition-specific tools (e.g., PDSS for panic, LSAS for social anxiety, PCL-5 for PTSD) provide better characterisation.
What is the first-line pharmacotherapy for GAD?
NICE recommends SSRIs (selective serotonin reuptake inhibitors) as first-line pharmacotherapy for GAD, with sertraline having the best evidence and tolerability profile. SNRIs (venlafaxine, duloxetine) are second-line. Pregabalin is also licensed for GAD and effective but carries misuse potential. Buspirone is used in some cases. Benzodiazepines are NOT recommended beyond 2–4 weeks due to dependence risk.
How does GAD-7 compare with PHQ-9 for comorbid anxiety-depression?
GAD-7 and PHQ-9 are frequently administered together as they measure complementary dimensions of common mental health presentations. Anxiety and depression co-occur in approximately 50% of patients with either condition. Combined GAD-7 + PHQ-9 administration takes less than 5 minutes and provides a comprehensive emotional wellbeing profile used in IAPT services to guide treatment pathway selection.
What is the functional impact item in GAD-7?
After completing the 7 scored items, GAD-7 includes an optional question asking how much these problems have made it difficult to do work, take care of things at home, or get along with other people — scored as not difficult at all, somewhat difficult, very difficult, or extremely difficult. This functional impairment item (not included in the total score) helps assess the clinical significance of the anxiety symptoms.
Can GAD-7 be used in adolescents?
The adult GAD-7 has been validated in adolescents aged 12–17 with good psychometric properties. The recommended clinical threshold in adolescents is the same (≥10), though some studies suggest lower thresholds may be more appropriate in younger age groups. The Spence Children's Anxiety Scale (SCAS) is an alternative specifically designed and validated for children and adolescents.
What are the first-line psychological treatments for GAD?
NICE CG113 recommends high-intensity cognitive behavioural therapy (CBT) as the first-line psychological treatment for GAD with 10 or more sessions. Applied relaxation therapy is an evidence-based alternative to CBT for GAD specifically. Low-intensity interventions (guided self-help, psychoeducation groups) are offered as step 2 for GAD-7 scores in the mild-to-moderate range with good self-management capability.
Is GAD-7 reliable as a self-completed tool?
In the context of Gad7, this depends on the specific inputs, assumptions, and goals of the user. The underlying formula provides a deterministic relationship between inputs and output, but real-world application requires interpreting the result within the broader context of health and medical practice. Professionals typically cross-reference calculator output with industry benchmarks, historical data, and regulatory requirements. For the most reliable results, ensure inputs are sourced from verified data, understand which assumptions the formula makes, and consider running multiple scenarios to bracket the range of likely outcomes.
Ammattilaisen vinkki
Use GAD-7 alongside PHQ-9 as a paired assessment — this takes under 5 minutes and provides a comprehensive anxiety-depression profile. In primary care, consider the combined score: high PHQ-9 with high GAD-7 indicates mixed anxiety-depressive disorder requiring integrated treatment. High GAD-7 with low PHQ-9 points more toward a primary anxiety disorder where GAD-focused CBT may be more appropriate than depression-focused approaches.
Tiesitkö?
The GAD-7 was developed in 2006 by Robert Spitzer — the same psychiatrist who led the revision of DSM-III in 1980, which fundamentally restructured psychiatric diagnostic classification. The PHQ-9 and GAD-7 are now used together in over 80 countries and have collectively been cited in over 10,000 peer-reviewed publications. Their combined 16-item assessment takes less than 5 minutes and provides more standardised clinical information than many 30-minute unstructured interviews.
Viitteet
- ›Spitzer RL et al. — A Brief Measure for Assessing Generalised Anxiety Disorder (Arch Intern Med 2006)
- ›NICE CG113 — Generalised Anxiety Disorder and Panic Disorder in Adults (2011, updated 2019)
- ›Löwe B et al. — Validation of GAD-7 in Primary Care (Medical Care 2008)
- ›Kroenke K et al. — Anxiety Disorders in Primary Care — Prevalence, Impairment (Ann Intern Med 2007)
- ›LITFL GAD-7 Anxiety Scale Reference